UK strikes deal for $90 million more Coronavirus Vaccines with Novavax and Johnson & Johnson

UK Strikes Deals for 90 Million More Coronavirus Vaccine Doses from Novavax and Johnson and Johnson

The UK government has entered into agreements with two drugmakers for buying their potential Covid-19 vaccine doses, the companies said on Friday.

As part of the deals, Johnson and Johnson’s Janssen Pharmaceutical unit will flexibly the British government with 30 million doses of its Covid-19 vaccine candidate. India’s Biological E-Signs Pact With Johnson and Johnson for Coronavirus Vaccine Production.

The UK government has likewise entered into an agreement with US biotech organization Novavax for the purchase of 60 million doses of its Covid-19 vaccine candidate NVX-CoV2373 and a Phase 3 clinical trial to assess the efficacy of the vaccine in the British population.

Under the terms of the agreement, Novavax will flexibly 60 million doses of NVX-CoV2373 to the UK beginning as early as the first quarter of 2021.

“It is encouraging that Novavax’s recent clinical data shows their vaccine triggers an immune response greater than that in patients who have recovered from the disease,” Kate Bingham, Chair of the UK Government’s Vaccines Taskforce said in a statement.

“We believe that Novavax has a profoundly innovative vaccine that could be the first in its group of protein-based vaccine options.”

With the two new deals, the UK has now placed orders for six experimental Covid-19 vaccines, taking its potential stockpile to 340 million doses, the BBC reported.

Novavax said the Phase 3 clinical trial will be a randomized, double-blind, placebo-controlled efficacy study in approximately 9,000 adults 18-85 years of age in the UK.

The trial is expected to begin in the third quarter of this year, with the UK government supporting and giving infrastructure to Novavax in the execution of the trial.

The trial will assess the ability of NVX-CoV2373 to protect against symptomatic Covid-19 disease just as evaluate antibody and T-cell responses.